Cannabis Law Report

OCTOBER 6, 2021

NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. About Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S. Child: care, health and development. 17 Aug 2021.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

DECEMBER 15, 2021

Australia’s medicines regulator has rejected a call to legalise psychedelic drugs for use in mental health settings. A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. But unfortunately this is Australia, Canberra & the TGA in that order!

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

MARCH 2, 2020

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. What’s the risk?

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

The Cannigma

MARCH 25, 2021

When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. Transfering nurses’ skills to cannabis medicine. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

The Joint Blog

APRIL 17, 2020

According to a new study in the Journal of Clinic Medicine , the use of Tetrahydrocannabinol (THC) could have adverse drug effects when combined with other medications due to drug-drug interactions. Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose.

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

JULY 27, 2021

Research opportunities such as the ORR expand the existing scientific knowledge base to better inform clinical decision making, and also dispels the stigma surrounding medicinal cannabis use.”. It is our hope that this study may embolden clinicians and patients to effectively partner in considering these treatments.”.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

The Cannigma

MAY 19, 2021

In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. In 2018, Epidolex became the first plant-derived cannabinoid prescription medicine to receive FDA approval. Shutterstock).

Law 137

Law Legalization Clinical Trials CBD 137

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. Remember, the pharmaceutical model is “this medicine addresses this specific target.”

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

DECEMBER 9, 2021

9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Thu, December 9, 2021, . NEW YORK , Dec. ” About MindMed.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. a necessary question to address as medical marijuana becomes more accessible. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. both recognized leaders in emergency medicine. The founding co-chairs are Andrew Monte, M.D., and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Otherside Farms

JANUARY 14, 2019

Marijuana has been used for centuries for medicinal purposes; however, it has earned a bad name due to its widespread abuse as an addictive substance. Here are five popular medicinal uses of cannabis with low concentration of the intoxicating chemical compound tetrahydrocannabinol (THC). Inflammation.

Clinical Trials 49

Clinical Trials Strains Therapy Medicine 49

Cannabis Law Report

AUGUST 25, 2021

“The acquisition of a distinctive company like Lucid illustrates FSD Pharma’s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way,” said Anthony Durkacz, Interim CEO of FSD Pharma. Strategic Highlights.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. published the first edition of the MAPS Bulletin , titled “ MDMA Can Become a Legal Medicine ,” and the FDA rejected the second MDMA study protocol submitted by MAPS. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 4, 2021

The poster presentation of the data was by Dr. Scott Tagawa , a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Project CBD

FEBRUARY 28, 2023

The following excerpt analyzes CBD marketing trends reported by the American Botanical Council, a membership organization that educates consumers, health care professionals, journalists, and others about the safe and effective use of medicinal plants. National Library of Medicine website. US Food & Drug Administration website.

CBD 144

CBD Seed-To-Sale Food Access 144

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Advance to FDA IND-enabling studies to support human clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

JUNE 7, 2021

It turns out that this blissful drug, MDMA, has the potential to be used effectively as a treatment for certain conditions- some of which are in urgent need of effective medical assistance. . But what are the medicinal benefits associated with this synthetic substance which led to the FDA’s support? What is MDMA?

Therapy 82

Therapy Treatment Conditions Clinical Trials 82

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40